Abeona Therapeutics annual operating margin
2010
2011
2012
2013
2014
2015
2016
2017
2018
2020
2021
2022
2023
2025
Abeona Therapeutics's operating margin was −1,536.91% for fiscal 2025.
View full Abeona Therapeutics company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −1,536.91% | −190.19 pp |
| 2023 | 2023-12-31 | −1,346.71% | +2254.06 pp |
| 2022 | 2022-12-31 | −3,600.78% | −606.24 pp |
| 2021 | 2021-12-31 | −2,994.53% | −2180.33 pp |
| 2020 | 2020-12-31 | −814.20% | +1125.96 pp |
| 2018 | 2018-12-31 | −1,940.16% | +1385.53 pp |
| 2017 | 2017-12-31 | −3,325.69% | −639.41 pp |
| 2016 | 2016-12-31 | −2,686.28% | −903.01 pp |
| 2015 | 2015-12-31 | −1,783.27% | −1444.78 pp |
| 2014 | 2014-12-31 | −338.49% | −152.20 pp |
| 2013 | 2013-12-31 | −186.29% | −88.29 pp |
| 2012 | 2012-12-31 | −98.00% | +330.27 pp |
| 2011 | 2011-12-31 | −428.28% | +1184.41 pp |
| 2010 | 2010-12-31 | −1,612.68% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −119.97% | +818.03 pp |
| Q1 2026 | 2026-03-31 | −264.14% | +536.66 pp |
| Q2 2025 | 2025-06-30 | −5,698.00% | +253.16 pp |
| Q2 2023 | 2023-06-30 | −301.54% | −212.29 pp |
| Q3 2022 | 2022-09-30 | −938.00% | +51.82 pp |
| Q2 2022 | 2022-06-30 | −800.80% | +732.41 pp |
| Q1 2022 | 2022-03-31 | −5,951.16% | −3939.29 pp |
| Q3 2020 | 2020-09-30 | −89.26% | +3980.51 pp |
| Q3 2018 | 2018-09-30 | −989.82% | +1458.58 pp |
| Q2 2018 | 2018-06-30 | −1,533.21% | +2356.19 pp |
| Q1 2018 | 2018-03-31 | −2,011.86% | +829.00 pp |
| Q4 2017 | 2017-12-31 | −4,069.77% | −1791.64 pp |
| Q3 2017 | 2017-09-30 | −2,448.40% | +363.55 pp |
| Q2 2017 | 2017-06-30 | −3,889.40% | −751.55 pp |
| Q1 2017 | 2017-03-31 | −2,840.86% | −219.58 pp |
| Q4 2016 | 2016-12-31 | −2,278.13% | +630.25 pp |
| Q3 2016 | 2016-09-30 | −2,811.96% | −649.15 pp |
| Q2 2016 | 2016-06-30 | −3,137.85% | −1674.38 pp |
| Q1 2016 | 2016-03-31 | −2,621.28% | −1845.31 pp |
| Q4 2015 | 2015-12-31 | −2,908.37% | −2708.80 pp |
| Q3 2015 | 2015-09-30 | −2,162.81% | −1894.59 pp |
| Q2 2015 | 2015-06-30 | −1,463.48% | −1178.86 pp |
| Q1 2015 | 2015-03-31 | −775.97% | −137.51 pp |
| Q4 2014 | 2014-12-31 | −199.57% | +222.65 pp |
| Q3 2014 | 2014-09-30 | −268.22% | +100.03 pp |
| Q2 2014 | 2014-06-30 | −284.62% | +126.73 pp |
| Q1 2014 | 2014-03-31 | −638.46% | −597.37 pp |
| Q4 2013 | 2013-12-31 | −422.22% | −301.05 pp |
| Q3 2013 | 2013-09-30 | −368.25% | −258.50 pp |
| Q2 2013 | 2013-06-30 | −411.35% | −200.91 pp |
| Q1 2013 | 2013-03-31 | −41.09% | −3.59 pp |
| Q4 2012 | 2012-12-31 | −121.17% | +218.87 pp |
| Q3 2012 | 2012-09-30 | −109.76% | +61.61 pp |
| Q2 2012 | 2012-06-30 | −210.43% | +1281.62 pp |
| Q1 2012 | 2012-03-31 | −37.51% | +1395.16 pp |
| Q4 2011 | 2011-12-31 | −340.04% | — |
| Q3 2011 | 2011-09-30 | −171.37% | — |
| Q2 2011 | 2011-06-30 | −1,492.05% | — |
| Q1 2011 | 2011-03-31 | −1,432.67% | — |
Over the last five reported fiscal years, Abeona Therapeutics's operating margin increased from −1,940.16% to −1,536.91%, a change of +403.25 percentage points. The latest reported quarter, Q2 2026, shows −119.97%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Abeona Therapeutics filings at SEC.gov ↗